Cautious Hold Rating for Bolt Biotherapeutics Amid Uncertain Clinical and Financial Outlook

H.C. Wainwright analyst Edward White has maintained their neutral stance on BOLT stock, giving a Hold rating today.

Edward White has given his Hold rating due to a combination of factors surrounding Bolt Biotherapeutics’ current financial and clinical status. The company has ongoing clinical trials for its candidates BDC-4182 and BDC-3042, but these are still in early stages with results expected in 2Q25. The lack of current data on the efficacy of these candidates means that they are not yet included in the valuation, which adds uncertainty to the company’s future prospects.
Additionally, Bolt Biotherapeutics reported no revenue for 4Q24 and a higher-than-expected loss per share, which has led to a downward revision of the EPS estimate for FY25. Despite having a cash runway through mid-2026, the absence of a clear revenue stream and the need for further data on their clinical trials contribute to the Hold rating. The rating reflects a cautious stance as the company awaits more clarity on its pipeline and potential partnerships for future development.

White covers the Healthcare sector, focusing on stocks such as Valneva, Chimerix, and Karyopharm Therapeutics. According to TipRanks, White has an average return of -1.8% and a 36.87% success rate on recommended stocks.

In another report released today, Stifel Nicolaus also maintained a Hold rating on the stock with a $1.25 price target.